Rivas-García Lorenzo, Méndez-Arriaga José Manuel, Jiménez-Falcao Sandra, Sánchez-Olivares Paula, Cristóbal-Cueto Pablo, Pinedo-Serrano Alejandro, López-Rosa Raquel, Sánchez-López Esther, Gómez-Ruiz Santiago, Galán-Moya Eva M
Instituto de Biomedicina (IB-UCLM), Campus de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
COMET-NANO Group, Departamento de Biología y Geología, Física y Química Inorgánica, ESCET, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain.
J Cell Mol Med. 2025 Aug;29(15):e70757. doi: 10.1111/jcmm.70757.
Breast cancer (BC) is the most diagnosed tumour worldwide and triple-negative breast carcinoma (TNBC) stands out among all subtypes due to its high aggressiveness and high mortality rate. Treatments for this subtype are limited to radio-and chemotherapy due to the lack of specific therapeutic targets. Nanomedicine emerges as an alternative to overcome actual therapy challenges. Here, we propose a novel nanosystem based on mesoporous silica nanoparticles (MSN) with a curcumin-palladium complex (PdCur) encapsulation that shows promising results against TNBC cells. The resulting nanomaterial, MSN-AP-PdCur, displayed an average size of 144 ± 7 nm, determined by transmission electron microscopy and quite good stability through various characterisation techniques. Antitumor activity assays showed a dose-dependent reduction of the cell metabolic activity of TNBC cells in vitro. Furthermore, the nanosystem mainly favoured the induction of two cell death pathways, such as apoptosis and autophagy, indicating its potential use as a nanomedicine-based therapeutic agent.
乳腺癌（BC）是全球诊断出最多的肿瘤，而三阴性乳腺癌（TNBC）在所有亚型中尤为突出，因其具有高侵袭性和高死亡率。由于缺乏特定的治疗靶点，该亚型的治疗方法仅限于放疗和化疗。纳米医学作为一种克服当前治疗挑战的替代方案应运而生。在此，我们提出了一种基于介孔二氧化硅纳米颗粒（MSN）的新型纳米系统，其包裹了姜黄素 - 钯配合物（PdCur），对TNBC细胞显示出有前景的结果。所得的纳米材料MSN - AP - PdCur，通过透射电子显微镜测定其平均尺寸为144 ± 7 nm，并且通过各种表征技术显示出相当好的稳定性。抗肿瘤活性测定表明，体外TNBC细胞的细胞代谢活性呈剂量依赖性降低。此外，该纳米系统主要促进了两种细胞死亡途径的诱导，如凋亡和自噬，表明其作为基于纳米医学的治疗剂的潜在用途。
